SER Steven Mintz buys $39K worth of shares
Sep 17, 2024, 1:32 AM
-2.76%
What does SER do
Serina Therapeutics, based in Alameda, California, is a clinical-stage biotechnology company developing drug candidates for neurological diseases, focusing on SER-252 for Parkinson's Disease. The company went public on November 29, 2018, and employs four people.
Steven Mintz bought 6,000 shares of SER on 12 September at $6.47 per share, worth a total of $39K. They now own 17,443 SER shares, or a 52% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.